senl103
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 21, 2023 (NCT06067581)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06067581 | Early Phase 1 (Phase 1) | Aug 21, 2023 | Hebei Senlang Biotechnology Inc., Ltd., Huazhong University of Science and Technology |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hebei Senlang Biotechnology Inc., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1